Yellow fever (YF) causes severe morbidity and mortality in Africa and South America. It is an arthropod-borne viral disease endemic to tropical regions of Africa and South America. Yellow fever virus (YFV) is transmitted by mosquitoes and frequently affects both non-human primates (NHPs) and humans. Neotropical primates (NTPs) are generally more severely afflicted by YFV than African primates. Asian primates appear not to be susceptible to this disease. Susceptibility varies among NTP species: asymptomatic infections are described in some NTP species, whereas severe epizootic mortality events are described in others. The genus Alouatta (howler monkeys) is considered to be the most susceptible among the NTPs. Epizootic events resulting in the death of thousands of NTPs have been recorded in recent history. As a result, YFV poses a threat to the survival of some NTP species. In most cases, NTPs are found dead without showing prior clinical signs. In cases where clinical signs are observed, they are mostly non-specific. Due to their high susceptibility, epizootic events in NTPs are used as epidemiological predictors for human YF outbreaks. YFV infection may be diagnosed by means of virus isolation, reverse transcription polymerase chain reaction, serology, histopathology, or immunohistochemistry. Animals that survive the disease develop neutralizing antibodies to YFV. Currently, no specific treatment is available. Sustained YF control strategies must rely on surveillance and accurate diagnostics to allow for early detection of outbreaks and rapid implementation of control measures. Prophylaxis should be based on a One Health perspective that recognizes the intricate interplay between human health, primate health, and the environment. Vaccines for YF are available, with the human 17DD vaccine effectively preventing disease in primates. However, mitigation strategies continue to rely more and more on vector control, preferably using eco-friendly methods. Climate change and human activities, and their impact on local ecology, are assumed to increase the risk of YF transmission in the next decades.
Yersinia pseudotuberculosis causes yersiniosis in a wide range of mammalian and avian taxa worldwide. This review aims to provide an overview of the current literature on yersiniosis in non-domesticated mammals and birds in captivity. Data on the prevalence of Y. pseudotuberculosis in captive populations are scarce. Transmission is primarily via the fecal–oral route, with wild rodents and birds as primary reservoirs. Predisposing factors to yersiniosis include young age, inclement weather, stress, and genetic factors. Symptoms are often non-specific, with sudden death occurring frequently, particularly in avian species. Gross pathological examination typically reveals multiple white-yellow foci in visceral organs, while histopathology demonstrates necrosis with central bacterial colonies. Ante-mortem diagnosis can be challenging as bacterial culture and isolation from fecal samples are often hindered by intermittent excretion and competition with other gastrointestinal flora. Although killed and subunit vaccine formulations have demonstrated limited protective efficacy, live attenuated strains may hold greater promise for inducing more robust and durable immunity. Y. pseudotuberculosis remains a significant threat to animal health, highlighting the need for faster and more reliable diagnostic techniques and the development of more effective treatment and prophylactic strategies.
Reproductive success in captive non-human primates (NHPs) has increased the demand for safe, effective, and reversible population control methods. This review provides an overview of the current literature on hormonal and non-hormonal contraceptives as reproductive control methods in NHPs. Where available, behavioral and welfare implications, as well as drug efficacy, reversibility, and associated adverse effects, are considered. However, a paucity of data exists for NHPs, particularly in regard to non-hormonal contraceptives, emphasizing the need for institutions to share their experiences with reproductive management techniques in the species under their care.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in a zoological institution were initially reported in March 2020. Since then, at least 94 peer-reviewed cases have been reported in zoos worldwide. Among the affected animals, nonhuman primates, carnivores, and artiodactyls appear to be most susceptible to infection, with the Felidae family accounting for the largest number of reported cases. Clinical symptoms tend to be mild across taxa; although, certain species exhibit increased susceptibility to disease. A variety of diagnostic tools are available, allowing for initial diagnostics and for the monitoring of infectious risk. Whilst supportive therapy proves sufficient in most cases, monoclonal antibody therapy has emerged as a promising additional treatment option. Effective transmission of SARS-CoV-2 in some species raises concerns over potential spillover and the formation of reservoirs. The occurrence of SARS-CoV-2 in a variety of animal species may contribute to the emergence of variants of concern due to altered viral evolutionary constraints. Consequently, this review emphasizes the need for effective biosecurity measures and surveillance strategies to prevent and control SARS-CoV-2 infections in zoological institutions.
This review summarizes the current understanding of how brevetoxins, produced by Karenia brevis during harmful algal blooms, impact sea turtle health. Sea turtles may be exposed to brevetoxins through ingestion, inhalation, maternal transfer, and potentially absorption through the skin. Brevetoxins bind to voltage-gated sodium channels in the central nervous system, disrupting cellular function and inducing neurological symptoms in affected sea turtles. Moreover, the current evidence suggests a broader and longer-term impact on sea turtle health beyond what is seen during stranding events. Diagnosis relies on the detection of brevetoxins in tissues and plasma from stranded turtles. The current treatment of choice, intravenous lipid emulsion therapy, may rapidly reduce symptoms and brevetoxin concentrations, improving survival rates. Monitoring, prevention, and control strategies for harmful algal blooms are discussed. However, as the frequency and severity of blooms are expected to increase due to climate change and increased environmental pollution, continued research is needed to better understand the sublethal effects of brevetoxins on sea turtles and the impact on hatchlings, as well as the pharmacokinetic mechanisms underlying brevetoxicosis. Moreover, research into the optimization of treatments may help to protect endangered sea turtle populations in the face of this growing threat.
Vaccination constitutes one of the most important means of preventing infectious disease in captive nonhuman primates (NHPs). Vaccination protocols for NHPs vary, as they are mostly guided by institutional preference, infection pressure, local availability, and recommendations by non-peer reviewed resources. Currently, no updated literature review about vaccination options for NHP is available. Therefore, we provide a detailed overview of published vaccination options for NHP. Our findings demonstrate that, while there are often insufficient scientific data to justify their use, the core vaccines used in most NHP species confer protection against tetanus, rabies, and measles. Where information is available, efficacy expectations, adverse effects, dosages and frequency of administration are provided. We advocate that the decision to vaccinate NHP for less common diseases, for which an off-label vaccine is available, should be grounded in a comprehensive risk assessment. This assessment should consider factors specific to the individual animal, the vaccine, the housing institution, the epidemiology of the disease, and relevant regulatory and ethical considerations.